/ /

  • linkedin
  • Increase Font
  • Sharebar

    Studying aqueous humour outflow with aqueous angiography

    With aqueous angiographic information, individualised MIGS placement may become possible

     

    Future perspectives

    Dr Huang notes some limitations in aqueous angiography. For example, currently, aqueous angiography with the Spectralis requires the FLEX module, which is a prototype stand only available to a handful of investigators in the world.

    Furthermore, the steps involved in aqueous angiography—arranging the camera, accessing the eye, delivering the tracer and taking the images—require time. Thus, while not insurmountable, continued evolution of the method with future iterations should “streamline the process beyond current constraints and make it accessible to all ophthalmologists”.

    Ultimately, future efforts should determine if aqueous angiography-guided MIGS provides better and more consistent results. If this is the case, “one could envision customised and targeted surgical placement of MIGS in each eye of every individual” for, potentially, better final IOP-lowering outcomes in the future, Dr Huang said.

    Additionally, angiography may allow us to better understand both normal and diseased aqueous humour outflow. Pharmacologically, aqueous angiography may help identify new drugs for IOP lowering as well. 

    Imagined to its greatest extent, aqueous angiography and individualised imaging-determined therapies supports the National Institute of Health’s goal to develop more customised patient care and personalised medicine.

    References

    1.     Keane PA, Sadda SR. Ophthalmology. 2014;121(12):2489-500.

    2.     Keller KE, et al. Invest Ophthalmol Vis Sci. 2011;52(8):5049-57.

    3.     Battista SA, et al. Invest Ophthalmol Vis Sci. 2008;49(12):5346-52.

    4.     Swaminathan SS, et al. Invest Ophthalmol Vis Sci. 2013;54(3):2035-47.

    5.     Saraswathy S, et al. PLoS One 2016;11(1):e0147176.

    6.     Huang AS, et al. Transl Vis Sci Technol. 2016;5(6):5.

    7.     Huang AS, et al. Invest Ophthalmol Vis Sci. 2016;57(11):4558-65.

    8.     Huang AS, et al. Ophthalmology. 2017.

    9.     Huang AS, et al. Ophthalmology. 2017.

    10.  Huang AS, Mohindroo C, Weinreb RN. J Clin Exp Ophthalmol. 2016;7(4).

    11.  Jacobs DS, et al. Ophthalmology. 2006;113(4):707-13.

    12.  Watson PG, Bovey E. Ophthalmology. 1985;92(1):1-11.

    13.  Marvasti AH, et al. Case Rep Ophthalmol. 2016;7(1):30-8.

    14.  Grieshaber MC, Pienaar A, Olivier J, Stegmann R. Invest Ophthalmol Vis Sci. 2010;51(3):1498-504.

    15.  Akil H, et al. PLoS One 2017;12(2):e0170476.

    E: [email protected]

    Dr Huang is an assistant professor, clinician-scientist and one of the founding members of the Doheny Eye Institute and University of California, Los Angeles, United States. His aqueous angiographic work is supported by Heidelberg Engineering and Glaukos Corporation.

     

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results